Please login to the form below

Not currently logged in
Email:
Password:

Trial success for Novartis' psoriasis drug

Novartis has presented data at the European Academy of Dermatology and Venereology Congress that demonstrates investigational psoriasis treatment AIN457 is effective in up to 81 per cent of patients

Novartis has presented data at the European Academy of Dermatology and Venereology (EADV) Congress in Lisbon, Portugal, that demonstrates investigational psoriasis treatment AIN457 is effective in up to 81 per cent of patients.

The company said one phase II study showed 81 per cent of patients receiving AIN457 150mg subcutaneously once a month experienced at least a 75 per cent improvement of psoriasis signs and symptoms.

A separate study demonstrated 83 per cent of patients who were given an intravenous starting dose of AIN457 experienced at least a 75 per cent improvement of symptoms. This compared to 10 per cent of patients on placebo.

The treatment, a fully human monoclonal antibody neutralizing interleukin-17A that may provide a new mechanism of action for the treatment of immune-mediated diseases, was also shown to be more effective when used early on in the therapeutic process.

Dr Kim Papp, dermatologist and director of research at Probity Medical Research, Waterloo, Ontario, Canada, said the results suggest that AIN457 could bring "considerable improvement" to the lives of patients with psoriasis, and emphasised the fast-acting action of the drug.

John Hohneker, global head of development for Integrated Hospital Care at Novartis, said: "We are encouraged by these positive phase II results and look forward to receiving the results of larger-scale and longer-term phase III studies with AIN457 which began this year."

24th October 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics